A majority 27% of the respondents opined that the disrupted clinical trials could take more than 12 months to return to normal, while 23% felt that four to six months may be enough and 22% were optimistic about witnessing normalcy in just three months.
Further, 15% of the respondents felt that it could take seven to nine months for disrupted clinical trials to return to normal followed by 13% who felt that it could take ten to 12 months.
The analysis is based on 731 responses received from readers of Clinical Trials Arena, a Verdict network site, between 08 July and 03 August.
The COVID-19 pandemic has disrupted various aspects of clinical trials including enrolment, supply chains, and trial initiation, according to GlobalData.